EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma

Karin G Schrenk, Wolfram Weschenfelder, Christian Spiegel, Abbas Agaimy, Robert Stöhr, Arndt Hartmann, Nikolaus Gaßler, Robert Drescher, Martin Freesmeyer, Amer Malouhi, Florian Bürckenmeyer, René Aschenbach und 5 weitere

Journal of Cancer Research and Clinical Oncology · 2023-08 · 149 (9) · 5493-5496

DOI: 10.1007/s00432-022-04496-y ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 05.12.2022. Verfasst von Karin G Schrenk und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Internal Oncology, Clinic of Internal Medicine II, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. karin.…. Hauptthemen laut MEDLINE: Sarcoma, Soft Tissue Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Jena.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33 -fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET -fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaSoft Tissue NeoplasmsLung NeoplasmsHumansNeoadjuvant TherapyPyrazolesPyridinesProtein Kinase InhibitorsProto-Oncogene Proteins c-retTranscription Factors

Stichwörter der Autor:innen

RET-fusionSarcomaSelpercatinibTRIM33Targeted therapy

Substanzen

selpercatinibPyrazolesPyridinesProtein Kinase InhibitorsRET protein, humanProto-Oncogene Proteins c-retTRIM33 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Hematology and Internal Oncology, Clinic of Internal Medicine II, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. karin.schrenk@med.uni-jena.de.
  • Clinic of Trauma-, Hand- and Reconstructive Surgery, University Hospital Jena, Jena, Germany.
  • Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Institute of Forensic Medicine, Section of Pathology, University Hospital Jena, Jena, Germany.
  • Clinic of Nuclear Medicine, University Hospital Jena, Jena, Germany.
  • Institute of Diagnostic and Interventional Radiology, University Hospital Jena, Jena, Germany.

Förderung

  • Universitätsklinikum Jena

Zitieren

APA

Schrenk, K. G., Weschenfelder, W., Spiegel, C., Agaimy, A., Stöhr, R., Hartmann, A., Gaßler, N., Drescher, R., Freesmeyer, M., Malouhi, A., Bürckenmeyer, F., Aschenbach, R., Teichgräber, U., Kögler, C., Vogt, M., Hofmann, G. O., & Hochhaus, A. (2023). Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. Journal of Cancer Research and Clinical Oncology, 149(9), 5493-5496. https://doi.org/10.1007/s00432-022-04496-y

Vancouver

Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, et al. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. Journal of Cancer Research and Clinical Oncology. 2023;149(9):5493-5496. doi:10.1007/s00432-022-04496-y

BibTeX
@article{Schrenk2023,
  author = {Schrenk, Karin G and Weschenfelder, Wolfram and Spiegel, Christian and Agaimy, Abbas and Stöhr, Robert and Hartmann, Arndt and Gaßler, Nikolaus and Drescher, Robert and Freesmeyer, Martin and Malouhi, Amer and Bürckenmeyer, Florian and Aschenbach, René and Teichgräber, Ulf and Kögler, Christine and Vogt, Matthias and Hofmann, Gunther O and Hochhaus, Andreas},
  title = {Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2023},
  volume = {149},
  number = {9},
  pages = {5493--5496},
  doi = {10.1007/s00432-022-04496-y}
}
Kostenlos starten →